European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending
37 Pages Posted: 20 Nov 2006 Last revised: 20 Feb 2022
There are 2 versions of this paper
European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending
Date Written: November 2006
Abstract
EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on research and development (R&D). Some differences have increased over time. In 1986, EU pharmaceutical R&D exceeded U.S. R&D by about 24 percent, but by 2004, EU R&D trailed U.S. R&D by about 15 percent. During these 19 years, U.S. R&D spending grew at a real annual compound rate of 8.8 percent, while EU R&D spending grew at a real 5.4 percent rate. Results show that EU consumers enjoyed much lower pharmaceutical price inflation, however, at a cost of 46 fewer new medicines introduced by EU firms and 1680 fewer EU research jobs.
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
By Kurt Richard Brekke, Astrid Grasdal, ...
-
Reference Pricing of Pharmaceuticals
By Kurt Richard Brekke, Ingrid Königbauer, ...
-
Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy
-
European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending
By Joseph H. Golec and John A. Vernon
-
By Kurt Richard Brekke, Tor Helge Holmas, ...
-
The Simple Economics of Risk-Sharing Agreements between the NHS and the Pharmaceutical Industry
-
Competition and the Reference Pricing Scheme for Pharmaceuticals
-
Competition and the Reference Pricing Scheme for Pharmaceuticals
-
Patents, Price Regulation and Innovation in the Pharmaceutical Industry
-
Margins and Market Shares: Pharmacy Incentives for Generic Substitution
By Kurt Richard Brekke, Tor Helge Holmas, ...